Novartis Recall of Excedrin Products Extends to Canada

Novartis Recall of Excedrin Products Extends to Canada

OTTAWA, ONTARIO, Jan 13, 2012 (MARKETWIRE via COMTEX) -- Health Canada is advising Canadians that Novartis Consumer Health Inc's U.S. recall ( http://www.novartis-otc.com/otc/index.html ) is now being extended to Canada. According to Novartis Consumer Health Canada Inc, the Canadian recall includes all lots (expiration dates of December 20, 2014 and earlier) for over-the-counter products, Excedrin Extra Strength Caplets and Excedrin Tension Headache Caplets (See photos below).

According to the FDA, reports were received in the U.S. of chipped and broken pills ( http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm286265.htm?source=govdelivery ) and inconsistent bottle packaging clearance practices, which could result in the bottles containing foreign tablets, caplets, or capsules. The U.S. FDA has informed consumers that mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended or receiving an unintended ingredient. This could potentially result in overdose, interaction with other medications a consumer may be taking, or an allergic reaction if the consumer is allergic to the unintended ingredient.

Canadians can be confident that Health Canada is monitoring the voluntary recall by Novartis Consumer Health Canada Inc. Should additional information be identified, Health Canada will take appropriate action and inform Canadians.

Health Canada reminds Canadians who have concerns about these products to consult with their health care practitioner. For information concerning the recall or how to return the affected product, consumers should directly contact Novartis Consumer Health Canada Inc's consumer relationship centre at the following number 1-888-788-8181.

To report suspected adverse reaction to these or other health products, please contact the Canada Vigilance Program of Health Canada toll-free at 1-866-234-2345, or complete a Canada Vigilance Reporting Form ( http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/ar-ei_form-eng.php ) and send to us using one of these methods:



-- Fax: 1-866-678-6789
-- E-mail: [email protected]

www.healthcanada.gc.ca/medeffect -- Mail: Canada Vigilance Program
Marketed Health Products Directorate
Ottawa, ON, Address Locator 0701C
K1A 0K9

An image of the product is available at the following address: http://media3.marketwire.com/docs/Excedrin_0113.pdf

Egalement disponible en francais

Contacts:
Media Inquiries:
Health Canada
613-957-2983

Public Inquiries:
613-957-2991
1-866-225-0709

SOURCE: Health Canada

 

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.